Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely III Medical Patients: An APEX Trial Substudy


Gibson C. M., Korjian S., Chi G., Daaboul Y., Jain P., Arbetter D., ...More

JOURNAL OF THE AMERICAN HEART ASSOCIATION, vol.6, no.7, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 6 Issue: 7
  • Publication Date: 2017
  • Doi Number: 10.1161/jaha.117.006015
  • Journal Name: JOURNAL OF THE AMERICAN HEART ASSOCIATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: death, intracranial hemorrhage, ischemic stroke, myocardial infarction, pulmonary embolism, venous thromboembolism, THROMBOPROPHYLAXIS
  • Hacettepe University Affiliated: Yes

Abstract

Background-Extended-duration betrixaban showed a significant reduction in venous thromboembolism in the APEX trial (Acute Medically III VTE Prevention With Extended Duration Betrixaban Study). Given the variable clinical impact of different efficacy and safety events, one approach to assess net clinical outcomes is to include only those events that are either fatal or cause irreversible harm.